Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
Smith L 2nd, Piatnitski EL, Kiselyov AS, Ouyang X, Chen X, Burdzovic-Wizemann S, Xu Y, Pan W, Chen X, Wang Y, Rosler RL, Patel SN, Chiang HH, Milligan DL, Columbus J, Wong WC, Doody JF, Hadari YR. Smith L 2nd, et al. Among authors: columbus j. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1643-6. doi: 10.1016/j.bmcl.2005.12.018. Epub 2006 Jan 18. Bioorg Med Chem Lett. 2006. PMID: 16412636
Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase.
Smith L 2nd, Wong WC, Kiselyov AS, Burdzovic-Wizemann S, Mao Y, Xu Y, Duncton MA, Kim K, Piatnitski EL, Doody JF, Wang Y, Rosler RL, Milligan D, Columbus J, Balagtas C, Lee SP, Konovalov A, Hadari YR. Smith L 2nd, et al. Among authors: columbus j. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5102-6. doi: 10.1016/j.bmcl.2006.07.031. Epub 2006 Aug 2. Bioorg Med Chem Lett. 2006. PMID: 16887347
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
Scott JD, DeMong DE, Greshock TJ, Basu K, Dai X, Harris J, Hruza A, Li SW, Lin SI, Liu H, Macala MK, Hu Z, Mei H, Zhang H, Walsh P, Poirier M, Shi ZC, Xiao L, Agnihotri G, Baptista MA, Columbus J, Fell MJ, Hyde LA, Kuvelkar R, Lin Y, Mirescu C, Morrow JA, Yin Z, Zhang X, Zhou X, Chang RK, Embrey MW, Sanders JM, Tiscia HE, Drolet RE, Kern JT, Sur SM, Renger JJ, Bilodeau MT, Kennedy ME, Parker EM, Stamford AW, Nargund R, McCauley JA, Miller MW. Scott JD, et al. Among authors: columbus j. J Med Chem. 2017 Apr 13;60(7):2983-2992. doi: 10.1021/acs.jmedchem.7b00045. Epub 2017 Mar 16. J Med Chem. 2017. PMID: 28245354
RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy.
Cuevas-Navarro A, Wagner M, Van R, Swain M, Mo S, Columbus J, Allison MR, Cheng A, Messing S, Turbyville TJ, Simanshu DK, Sale MJ, McCormick F, Stephen AG, Castel P. Cuevas-Navarro A, et al. Among authors: columbus j. Sci Adv. 2023 Jul 14;9(28):eadf4766. doi: 10.1126/sciadv.adf4766. Epub 2023 Jul 14. Sci Adv. 2023. PMID: 37450595 Free PMC article.
30 results